Eli Lilly shares rose 4% on Monday, driven by compelling new data for its next-generation obesity drug, retatrutide, with analysts and investors expecting it to extend the drugmaker's lead in the booming weight-loss market.
Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity, at the American Diabetes Association meeting in New Orleans.
